Racial differences in measures of glycemia in the Vitamin D and Type 2 Diabetes (D2d) Study: a secondary analysis of a randomized trial.

Mary K Rhee, Cyrus V Desouza, Lisa M Neff, Ranee Chatterjee, Daniel S Hsia, Erin S LeBlanc, Samuel Dagogo-Jack, Anastassios G Pittas, Jason Nelson, Richard E Pratley, Neda Rasouli, Anne M Peters

Journal: BMJ open diabetes research & care 2024;12(1):

PMID: 38350671

Abstract

INTRODUCTION

Understanding how race may influence the association between A1c and glycemia can improve diabetes screening. We sought to determine whether, for a given A1c level, glucose levels during an oral glucose tolerance test (OGTT) differed by race.

RESEARCH DESIGN AND METHODS

From data collected at 22 US clinical sites, we conducted a cross-sectional study of concurrently measured A1c and OGTT and observational longitudinal follow-up of the subset with high-risk pre-diabetes. Numerical integration methods were used to calculate area under the glycemic curve (AUC) during OGTT and least squares regression model to estimate A1c for a given AUC by race, controlling for potential confounders.

RESULTS

1016 black, 2658 white, and 193 Asian persons at risk of diabetes were included in cross-sectional analysis. Of these, 2154 with high-risk pre-diabetes were followed for 2.5 years. For a given A1c level, AUC was lower in black versus white participants. After adjustment for potential confounders, A1c levels for a given AUC quintile were 0.15-0.20 and 0.02-0.19 percentage points higher in black and Asian compared with white participants, respectively (p<0.05). In longitudinal analyses, black participants were more likely to be diagnosed with diabetes by A1c than white participants (28% vs 10%, respectively; p<0.01). Black and Asian participants were less likely to be diagnosed by fasting glucose than white participants (16% vs 15% vs 37%, respectively; p<0.05). Black participants with A1c levels in the lower-level quintiles had greater increase in A1c over time compared with white participants.

CONCLUSIONS

Use of additional testing beyond A1c to screen for diabetes may better stratify diabetes risk in the diverse US population.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Address: Kaiser Permanente Center for Health Research, Portland, Oregon, USA [email protected].; Division of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, Massachusetts, USA.; Tufts Medical Center, Boston, Massachusetts, USA.; Internal Medicine, Duke University, Durham, North Carolina, USA.; Endocrinology, Metabolism and Diabetes, University of Colorado Denver School of Medicine, Aurora, Colorado, USA.; Endocrinology, VA Eastern Colorado Health Care System, Denver, Colorado, USA.; Medicine/Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, Georgia, USA.; Translational Research Institute, AdventHealth Research Institute, Orlando, Florida, USA.; University of Nebraska Medical Center, Omaha, Nebraska, USA.; Northwestern Medicine, Chicago, Illinois, USA.; Endocrinology, USC, Manhattan Beach, California, USA.; Division of Endocrinology, Diabetes & Metabolism General Clinical Research Center, University of Tennessee Health Science Center, Memphis, Tennessee, USA.; Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.